news
Decoy ACE2 receptors could be promising COVID-19 infection-preventing drug
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
List view / Grid view
Proteomics
news
Novel tuberculosis transport protein could be target of new treatments
Cryogenic electron microscopy revealed that the vitamin B12 transporter on Mycobacterium tuberculosis acts like a non-selective sluice, transporting both the vitamin and antibiotics.
news
Nafamostat inhibits SARS-CoV-2 infection, preventing COVID-19 transmission
Researchers have demonstrated that Nafamostat mesylate (Fusan) can inhibit SARS-CoV-2 Spike protein-initiated membrane fusion at concentrations likely achievable and safe in patients.
news
TAp63, miRNAs and AURKA: novel cutaneous squamous cell carcinoma drug targets
The TAp63 tumour suppressor protein, two micro RNAs (miRNAs) and the AURKA gene can all suppress cutaneous squamous cell carcinoma (cuSCC) development, find researchers.
news
Researchers optimise PROTAC technology to dispose of cancer proteins
Researchers have optimised PROTAC substances to degrade and dispose of proteins that support cancers, by customising their structure and selecting the best ligases.
article
Host pathways in coronavirus replication and COVID-19 pre-clinical drug target identification using proteomic and chemoinformatic analysis
The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains. Here, Joseph Steward highlights key findings of recent research.
news
Imaging technique allows study of early stage Alzheimer’s disease
Scientists used optical photothermal spectroscopy (O-PTIR) to image murine neurons affected by early stage Alzheimer’s disease, providing insight into the progression of the disease.
news
Map of COVID-19 and human protein interactions reveals drug targets
Researchers have identified which SARS-CoV-2 proteins physically associate with proteins in human cells, revealing potential drug targets to treat the COVID-19 coronavirus.
article
Targeted protein degradation: the next wave of therapeutics
Using the ubiquitin-proteasome system to fight inflammatory conditions could provide more treatment options for patients. Dr Jared Gollob from Kymera Therapeutics explains why targeted protein degradation is the way forward for autoinflammatory and autoimmune disease therapies.
news
Preliminary SARS-CoV-2 protease inhibitor shows efficacy in mice
Using X-ray crystallography, researchers have revealed the structure of the SARS-CoV-2 main protease, designing an inhibitor to bind to this target and prevent viral replication.
article
Where could bioengineering and technological advances take drug discovery?
Drug Target Review explores the findings of a recent review of molecular, cellular, multi-cellular and tissue engineering and modelling technologies for drug design.
news
Novel biocompatible microparticles can be created using heat and light
Scientists have demonstrated an innovative technique for creating microparticles for tissue engineering out of a combination of disordered and partially ordered proteins.
news
3D visualisation of COVID-19 surface released for researchers
A new 3D model of the surface of the coronavirus COVID-19 has been released, to aid researchers in the development of a treatment.
news
Researchers work to create a COVID-19 viral epitope map
The team used data from SARS-CoV to identify possible viral epitopes that vaccines could include to stimulate an immune response.
news
Copper ions could be key to blocking cancer metastasis
Researchers have identified that copper ions and their protein transporters, such as Atox1, are key to cancer cell movement and could be targeted by therapies.
